Élan Maintenance Note: June 2026

Medicine names, trial headlines and access routes change. Patient biology changes more slowly. Appetite can return after treatment stops. Gastrointestinal side effects can interrupt nutrition and training. Weight regain is common enough after semaglutide withdrawal that maintenance planning should start early, not after regain has already happened.

Medication status matters before expectations rise

Oral treatment can sound simpler than injections, but each medicine has its own indication, dose, administration rules and evidence stage. Current EU product information matters more than headlines.

• Rybelsus, oral semaglutide: EU product information states that it is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It is not an EU weight-management indication. It must be taken on an empty stomach with up to 120 mL water, then the patient waits at least 30 minutes before eating, drinking or taking other oral medicines.
• Ozempic, semaglutide injection: EU product information states that it is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It is not an EU weight-management indication.
• Wegovy, semaglutide 2.4 mg: EU product information states that it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with obesity or overweight plus at least one weight-related comorbidity, and in adolescents aged 12 years and above with obesity and body weight above 60 kg.
• Mounjaro, tirzepatide: EU product information states that it is indicated in adults for type 2 diabetes under product criteria and for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight plus at least one weight-related comorbidity.
• Orforglipron and amycretin: these are investigational or availability-dependent medicines for patients in Estonia. Published human trials are useful watchlist evidence, not a reason to start, stop or switch treatment outside a clinician-led plan.

What matters for patients

The most useful question is not only “Which drug is strongest?” It is “Which system helps me maintain the result safely?”

• Can I eat enough protein and overall food to stay nourished?
• Can I preserve or build strength while losing weight?
• Can side effects be reviewed early, before intake and training collapse?
• Can I afford, tolerate and access the treatment long enough for a realistic plan?
• Do I have a clinician-led plan for plateaus, medication transitions, pregnancy planning, procedures or stopping?

If the answer is no, a stronger medicine may create a faster result without a stronger maintenance system.

Routine review versus urgent help

Constipation, nausea, reflux, fatigue and poor food quality are routine reasons to contact the prescribing clinician early. They should not be ignored, but they are not all emergencies.

Seek urgent medical help for severe or persistent abdominal pain, persistent vomiting or inability to keep fluids down, dehydration, severe weakness or collapse, symptoms of low blood sugar if you also use insulin or sulfonylureas, and sudden or rapidly worsening vision symptoms. Do not stop, restart, double or adjust GLP-1 or GIP/GLP-1 doses without the prescribing clinician unless emergency medical advice tells you to.

If you are pregnant, trying to conceive, could become pregnant or breastfeeding, discuss this before starting, continuing, stopping or changing semaglutide or tirzepatide treatment. Current EMA product information includes contraception and pregnancy-planning warnings, including stopping semaglutide at least 2 months before a planned pregnancy and tirzepatide at least 1 month before a planned pregnancy.

Why maintenance is the clinical strategy

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg and lifestyle intervention regained about two-thirds of their prior weight loss during one year of off-treatment follow-up. That does not prove every patient will regain the same amount. It does show why stopping should not be treated as the end of care.

Weight change is multifactorial. Food intake often has a larger direct effect on the scale than exercise, but exercise remains central for health, strength, glucose handling, mood, independence and weight maintenance. Rapid, unexplained or medically concerning weight change deserves clinical review.

Élan view

We disagree with treating weight loss as a short campaign. The body does not care that a subscription ended, a wedding passed or a target date arrived. Maintenance requires a system: food structure, resistance training, side-effect management, medication review and follow-up.

The next stage of obesity medicine will not be only about stronger drugs. It will also be about who can help patients stay well after the first weight-loss phase.

Primary and official sources

1. European Medicines Agency. Rybelsus EPAR product information. Oral semaglutide indication, administration instructions, pregnancy, breastfeeding and safety warnings. EMA product information.
2. European Medicines Agency. Ozempic EPAR product information. Semaglutide injection type 2 diabetes indication and safety warnings. EMA product information.
3. European Medicines Agency. Wegovy EPAR product information. Semaglutide 2.4 mg weight-management indication and safety warnings. EMA product information.
4. European Medicines Agency. Mounjaro EPAR product information. Tirzepatide type 2 diabetes and weight-management indications, gastric-emptying, contraception, pregnancy and safety warnings. EMA product information.
5. Wilding JPH et al. Diabetes, Obesity and Metabolism. 2022. STEP 1 trial extension, exploratory off-treatment extension, n=327. After withdrawal of semaglutide 2.4 mg and lifestyle intervention, participants regained about two-thirds of prior weight loss over one year. Novo Nordisk sponsorship and conflicts disclosed. PubMed.
6. Wharton S et al. New England Journal of Medicine. 2023. Phase 2 randomized trial of orforglipron in adults with obesity or overweight plus comorbidity, n=272, funded by Eli Lilly. PubMed.
7. Ma X et al. Diabetes Therapy. 2024. Phase 1 randomized crossover studies of food consumption with orforglipron in healthy participants, study A n=12 and study B n=34, Eli Lilly employee/shareholder conflicts disclosed. PubMed.
8. Knop FK et al. Lancet. 2023. OASIS 1, phase 3 randomized trial of oral semaglutide 50 mg in adults with overweight or obesity, n=667, funded by Novo Nordisk. This does not change EU product indication boundaries. PubMed.
9. Gasiorek A et al. Lancet. 2025. First-in-human phase 1 randomized placebo-controlled multipart trial of amycretin in adults with overweight or obesity, n=144, funded by Novo Nordisk. Novo Nordisk employee/shareholder conflicts and ICON funding were disclosed. PubMed.
10. Jensen MD et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation and Obesity. 2014. Professional guideline supporting diet, physical activity and behavioural strategies in weight management. PubMed.
11. Johns DJ et al. Journal of the Academy of Nutrition and Dietetics. 2014. Systematic review and meta-analysis comparing diet, exercise and combined behavioural weight-management programmes. PubMed.